Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | THRA | P10827 | 8/20 | 0.65 |
| ▸ | THRB | P10828 | 8/20 | 0.65 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897754 | 0.81 | THRA (0.76) | FFAR1THRATHRBESR1NR3C1 | |
| SCHEMBL4896366 | 0.81 | THRA (0.71) | FFAR1THRATHRBESR1NR3C1 | |
| SCHEMBL9656045 | 0.80 | CYSLTR1 (0.85) | FFAR1AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8649544 | 0.80 | FFAR1 (0.97) | FFAR1AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL4896426 | 0.78 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL4896419 | 0.78 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9581742 | 0.77 | FFAR1 (0.68) | FFAR1AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL7454187 | 0.77 | CYSLTR1 (0.77) | FFAR1AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9034967 | 0.77 | FFAR1 (0.55) | FFAR1AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL4893191 | 0.77 | THRA (0.65) | FFAR1AKR1B1THRATHRBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | FFAR1 43/4885AKR1B1 130/4885THRA 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.